Aims: To investigate the efficacy and safety of insulin degludec/liraglutide (IDegLira) compared with its individual components in Japanese people with type 2 diabetes (T2D) uncontrolled on an oral antidiabetic drug (OAD).
Japan's ageing population and changes in lifestyle factors, including diet and physical activity. 5, 6 Impaired insulin secretion is considered more common among Japanese people with T2D compared with white people, probably because of differences in body composition between these populations. 7, 8 Due to the progressive nature of T2D and associated deterioration of β-cell function, most patients will eventually require treatment intensification to maintain glycaemic targets. Japanese clinical practice guidelines emphasize treatment individualization and intensification with oral antidiabetic drugs (OADs), glucagon-like peptide-1 receptor agonists (GLP-1RAs) and basal or premixed insulin. 9 Basal insulin is an effective therapy for reducing fasting plasma glucose (FPG) levels, but it is associated with considerable risk of hypoglycaemia and weight gain. [10] [11] [12] GLP-1RAs augment glucose-dependent insulin secretion, as well as preserving β-cell function, delaying gastric emptying, promoting weight loss and increasing insulin sensitivity. 13 The complementary actions of insulin and GLP-1RAs target multiple pathophysiological defects involved in T2D, and combining both therapies together can reduce glycated haemoglobin (HbA1c) levels with lower risk of hypoglycaemia and weight gain compared with basal insulin alone. [14] [15] [16] [17] However, this burdens patients with two different treatment regimens, which may limit treatment adherence and intensification. 18, 19 Insulin degludec/liraglutide (IDegLira) is a fixed-ratio soluble combination of insulin degludec (degludec) and the GLP-1RA liraglutide (100 U and 3.6 mg/mL, respectively), which allows once-daily administration of both active ingredients with a single injection. The efficacy and safety of IDegLira has been investigated in a number of patient populations in the DUAL clinical trial programme. [20] [21] [22] [23] [24] [25] [26] [27] [28] Based on evidence from these trials, IDegLira received regulatory approval from the European Medicines Agency and the US Food and Drug Administration (FDA). 29, 30 The global DUAL I trial, which encompassed insulin-naïve participants with T2D, demonstrated that treatment with IDegLira results in improved glycaemic control compared with each component administered separately, whilst mitigating the side effects associated with each, including the gastrointestinal side effects associated with liraglutide. 20 The aim of the present study was to confirm the efficacy and safety of IDegLira compared with each of its components in Japanese people with T2D inadequately controlled on one OAD.
| MATERIALS AND METHODS

| Study design and participants
This 52-week, multicentre, randomized, open-label, three-arm parallel-group trial investigated the efficacy and safety of IDegLira versus each of its components, degludec and liraglutide ( Figure 1 ). The trial consisted of a 2-week screening period and a 52-week treatment period. Participants were Japanese adults (aged ≥20 years) with HbA1c levels of 53-97 mmol/mol (7.0%-11.0%) and a body mass index (BMI) of ≥20 kg/m 2 , who had been diagnosed with T2D ≥6 months prior to screening and who were on stable therapy with one of six OAD types for at least 60 days prior to screening. Permitted OADs were aligned with Japanese clinical practice guidelines: α-glucosidase inhibitors; thiazolidinediones; sodium-glucose co-transporter-2 inhibitors; glinides; metformin; or sulphonylureas. 9 The protocol was approved by independent ethics committees or institutional review boards at all participating institutions, and the 
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| Treatment
IDegLira and degludec were administered once daily. Recommended starting doses were 10 dose steps of IDegLira (10 U degludec +0.36 mg liraglutide) or 10 U of degludec. Doses were adjusted twice weekly in increments of ±2 U, aiming for a mean pre-breakfast selfmonitored blood glucose (SMBG; mean from 3 consecutive days) target range of 4.0-5.0 mmol/L (72-90 mg/dL; Table S1 ). SMBG was assessed using a glucose meter, calibrated to plasma equivalent values. The maximum dose of IDegLira was 50 dose steps, which delivers the maximum licensed liraglutide dose for diabetes (50 U degludec/1.8 mg liraglutide) 31 ; there was no maximum dose for degludec.
Liraglutide was administered once daily. Liraglutide was initiated at 0.3 mg and increased by 0.3 mg each week over a 6-week period up to the maximum dose of 1.8 mg. Temporary dose reductions for <1 week were only allowed for safety reasons. OAD treatment continued unchanged at pre-trial doses; however, in case of safety concerns the dose could be reduced at the discretion of the investigator.
| Randomization and stratification
Participants were randomized 1:1:1, via a centralized allocation using an interactive web response system, to receive either IDegLira, degludec or liraglutide, each in combination with pre-trial OAD. Participants were stratified by type of pre-trial OAD treatment to ensure an even distribution of each of the six OAD types across the three treatment arms. 
| Endpoints
| Statistical analyses
The main study objective was jointly confirming the non-inferiority of IDegLira to insulin degludec alone with an upper 95% confidence interval (CI) margin of 0.3%, and the superiority of IDegLira to liraglutide alone with a lower 95% CI margin of 0% (with respect to change in HbA1c at 26 weeks). The sample size was determined using a t-statistic under the assumption of a one-sided test with a type I error rate of 2.5% and a standard deviation of 1.0% for both the superiority and non-inferiority testing.
For sample size calculations, the mean difference between treatments in change from baseline in HbA1c after 52 weeks was assumed to be −0.1% for non-inferiority and −0.3% for superiority testing. The per-protocol analysis set (assumed to be 85% of the randomized participant population) was used for the power calculation for non-inferiority, while the full analysis set was used for superiority. Based on these assumptions, a sample size of 807 participants would provide a non-inferiority power of 98.9% and a superiority power of 93.5%, giving an overall power for meeting the primary objective of 92.5%. A non-inferiority margin for the difference in the change from baseline in HbA1c after 52 weeks of treatment of 0.3% was selected based on existing FDA guidance, and is considered to be the minimal clinically significant change for HbA1c level. 32 To ensure that the overall type I error rate was not inflated, a hierarchical testing procedure was used. If the primary hypotheses were confirmed in change in HbA1c (ie, IDegLira superiority to liraglutide and non-inferiority to degludec), the secondary confirmatory tests were performed for superiority of IDegLira versus degludec following and using a mixed model for repeated measurements and a pattern mixture model approach mimicking an intention-to-treat scenario.
3 | RESULTS
| Participants
A total of 819 participants were randomized and treated with either IDegLira (n = 275), degludec (n = 271) or liraglutide (n = 273), all in combination with pre-trial OAD ( Figure S1 ). In total 54 participants withdrew from the trial; 21 (7.6%) in the IDegLira group, 23 (8.5%) in the IDeg group and 10 (3.7%) in the liraglutide group. The level of glycaemic control demonstrated with IDegLira was supported by the secondary endpoint, achievement of predefined HbA1c targets ( Figure S2 ). 
| Body weight
After 52 weeks, there was a significantly smaller increase in body weight with IDegLira (2.9 kg) versus degludec (4.1 kg; Figure 2B ) with an ETD of −1.19 kg (95% CI −1.80; −0.59; P = .0001 [P-value for superiority]). The mean change from baseline in body weight was −1.0 kg with liraglutide versus 2.9 kg with IDegLira ( Figure 2B ), representing an ETD of 3.89 kg (95% CI 3.29; 4.49; P < .0001).
An exploratory analysis showed there was no significant interaction between background OAD therapy and treatment for the EOT, end of trial; FPG, fasting plasma glucose; IDegLira, insulin degludec/liraglutide endpoint change in body weight; there was no effect of pre-trial OAD treatment on the differences between IDegLira and comparator.
| Hypoglycaemic episodes
The cumulative incidence of severe or blood glucose-confirmed hypoglycaemia is shown in Figure 3 . 
| Dose
The mean insulin doses during the first week were similar in the IDegLira Figure S3B ).
Of the participants randomized to IDegLira, 17.1% (n = 47) were on the maximum dose of 50 dose steps, and 74.5% of these participants achieved the target of HbA1c <53 mmol/mol (<7.0%) at end of trial.
| Fasting plasma glucose
The mean FPG levels over time are shown in Figure 2C . After 52 weeks of treatment, change from baseline in mean FPG was similar for IDegLira 
| Self-monitored blood glucose
The mean nine-point SMBG profiles decreased across all groups throughout the trial ( Figure S4 ). After 52 weeks, SMBG profiles showed statistically significantly lower pre-and post-prandial glucose concentrations for IDegLira compared with degludec and liraglutide at all timepoints (except for pre-breakfast and at 4:00 AM, which were similar between IDegLira and degludec).
After 52 weeks of treatment, the reduction from baseline in prandial glucose increments was statistically significantly greater with 
| Lipid profile
There was a statistically significant difference, in favour of IDegLira, for total cholesterol (vs. degludec and liraglutide), LDL cholesterol (vs. degludec) and free fatty acids (vs. liraglutide), and a statistically significant difference in HDL cholesterol in favour of liraglutide versus IDegLira (Table S2 ).
| Adverse events
The percentage of participants experiencing at least one AE was similar in each treatment group. The most frequently reported AEs were infections, with viral upper respiratory tract infection experienced by over one-third of participants in each treatment group ( respectively. There were three events of elevated calcitonin (one with IDegLira and two with liraglutide).
| Serious adverse events
The percentage of participants experiencing at least one serious adverse event (SAE) was 6.2% in the IDegLira group, 4.8% in the degludec group and 5.1% in the liraglutide group. The majority of SAEs were considered unlikely to be related to trial product ( with degludec in previous trials. 26 There was a significantly lower rate of severe or blood glucose-confirmed hypoglycaemic episodes with liraglutide compared with IDegLira. This outcome was expected, because of the presence of the insulin component and the glucosedependent mode of action of GLP-1RAs. 33 A significantly smaller increase in body weight was seen with IDegLira (2.9 kg) compared with degludec (4.1 kg), probably as a result of the weight-reducing effect of liraglutide. 20 This significant difference is in alignment with findings from the global trial programme. 20 The weight gain associated with IDegLira treatment is in contrast to the modest weight loss (−0.5 kg) observed with IDegLira in the global DUAL I trial, 20 which could be attributed to differences in background OAD therapy between the global DUAL I extension trial and the present trial, and/or the difference in the relationship between BMI, insulin resistance and diabetes development in Japanese and white people. 7, [34] [35] [36] When IDegLira was used, the mean daily doses of liraglutide and degludec were both lower compared with using the respective monotherapies after 52 weeks. In the liraglutide group, the daily dose reached the maximum licensed dose for diabetes of 1.8 mg by week 6, whereas in the IDegLira group, the actual daily liraglutide dose remained stable from week 9 onwards at~1.0 mg. This demonstrates a clinical advantage of using the fixed-dose combination injection compared with the monotherapies alone.
There were no unexpected safety or tolerability issues identified with IDegLira, and the reported AEs were consistent with those of liraglutide or degludec. 37, 38 Treatment with IDegLira also resulted in fewer gastrointestinal side effects compared with liraglutide treatment alone.
The DUAL I Japan trial aimed to compare the efficacy and safety of IDegLira with its components given alone in Japanese patients with T2D. Comparing IDegLira with the free combination of its components was beyond the scope of the present trial and may be perceived as a study limitation. Nonetheless, co-administration of degludec and liraglutide within a single daily injection provides a simpler regimen than administering these components separately, and may help to overcome clinical inertia with respect to intensifying therapy.
In conclusion, in comparison with the individual components of IDegLira, the fixed-ratio combination offers Japanese participants with T2D who have been on stable OAD therapy a simplified treatment regimen with the benefits of improved glycaemic control, a low risk of hypoglycaemia and less weight gain than insulin treatment alone.
